keyword
MENU ▼
Read by QxMD icon Read
search

"RSV vaccine"

keyword
https://www.readbyqxmd.com/read/28722020/a-critical-role-of-gas6-axl-signal-in-allergic-airway-responses-during-rsv-vaccine-enhanced-disease
#1
Takehiko Shibata, Manabu Ato
Respiratory syncytial virus (RSV) is a common virus that causes lower respiratory infections across a wide range of ages. A licensed RSV vaccine is not available because vaccination with formalin-inactivated RSV (FI-RSV) and the subsequent RSV infection cause not only insufficient induction of neutralizing antibodies but also severe allergic airway responses, termed FI-RSV vaccine enhanced disease (FI-RSV VED). However, the underlying mechanism has not been identified, although a Th2-biased immune response is known to be a hallmark of this disease...
July 19, 2017: Immunology and Cell Biology
https://www.readbyqxmd.com/read/28702175/costs-of-hospitalization-with-respiratory-syncytial-virus-illness-among-children-aged-5-years-and-the-financial-impact-on-households-in-bangladesh-2010
#2
Mejbah Uddin Bhuiyan, Stephen P Luby, Nadia Ishrat Alamgir, Nusrat Homaira, Katharine Sturm-Ramirez, Emily S Gurley, Jaynal Abedin, Rashid Uz Zaman, Asm Alamgir, Mahmudur Rahman, Ismael R Ortega-Sanchez, Eduardo Azziz-Baumgartner
BACKGROUND: Respiratory syncytial virus (RSV) is the leading cause of acute respiratory illness in young children and results in significant economic burden. There is no vaccine to prevent RSV illness but a number of vaccines are in development. We conducted this study to estimate the costs of severe RSV illness requiring hospitalization among children <5 years and associated financial impact on households in Bangladesh. Data of this study could be useful for RSV vaccine development and also the value of various preventive strategies, including use of an RSV vaccine in children if one becomes available...
June 2017: Journal of Global Health
https://www.readbyqxmd.com/read/28689664/global-regional-and-national-disease-burden-estimates-of-acute-lower-respiratory-infections-due-to-respiratory-syncytial-virus-in-young-children-in-2015-a-systematic-review-and-modelling-study
#3
Ting Shi, David A McAllister, Katherine L O'Brien, Eric A F Simoes, Shabir A Madhi, Bradford D Gessner, Fernando P Polack, Evelyn Balsells, Sozinho Acacio, Claudia Aguayo, Issifou Alassani, Asad Ali, Martin Antonio, Shally Awasthi, Juliet O Awori, Eduardo Azziz-Baumgartner, Henry C Baggett, Vicky L Baillie, Angel Balmaseda, Alfredo Barahona, Sudha Basnet, Quique Bassat, Wilma Basualdo, Godfrey Bigogo, Louis Bont, Robert F Breiman, W Abdullah Brooks, Shobha Broor, Nigel Bruce, Dana Bruden, Philippe Buchy, Stuart Campbell, Phyllis Carosone-Link, Mandeep Chadha, James Chipeta, Monidarin Chou, Wilfrido Clara, Cheryl Cohen, Elizabeth de Cuellar, Duc-Anh Dang, Budragchaagiin Dash-Yandag, Maria Deloria-Knoll, Mukesh Dherani, Tekchheng Eap, Bernard E Ebruke, Marcela Echavarria, Carla Cecília de Freitas Lázaro Emediato, Rodrigo A Fasce, Daniel R Feikin, Luzhao Feng, Angela Gentile, Aubree Gordon, Doli Goswami, Sophie Goyet, Michelle Groome, Natasha Halasa, Siddhivinayak Hirve, Nusrat Homaira, Stephen R C Howie, Jorge Jara, Imane Jroundi, Cissy B Kartasasmita, Najwa Khuri-Bulos, Karen L Kotloff, Anand Krishnan, Romina Libster, Olga Lopez, Marilla G Lucero, Florencia Lucion, Socorro P Lupisan, Debora N Marcone, John P McCracken, Mario Mejia, Jennifer C Moisi, Joel M Montgomery, David P Moore, Cinta Moraleda, Jocelyn Moyes, Patrick Munywoki, Kuswandewi Mutyara, Mark P Nicol, D James Nokes, Pagbajabyn Nymadawa, Maria Tereza da Costa Oliveira, Histoshi Oshitani, Nitin Pandey, Gláucia Paranhos-Baccalà, Lia N Phillips, Valentina Sanchez Picot, Mustafizur Rahman, Mala Rakoto-Andrianarivelo, Zeba A Rasmussen, Barbara A Rath, Annick Robinson, Candice Romero, Graciela Russomando, Vahid Salimi, Pongpun Sawatwong, Nienke Scheltema, Brunhilde Schweiger, J Anthony G Scott, Phil Seidenberg, Kunling Shen, Rosalyn Singleton, Viviana Sotomayor, Tor A Strand, Agustinus Sutanto, Mariam Sylla, Milagritos D Tapia, Somsak Thamthitiwat, Elizabeth D Thomas, Rafal Tokarz, Claudia Turner, Marietjie Venter, Sunthareeya Waicharoen, Jianwei Wang, Wanitda Watthanaworawit, Lay-Myint Yoshida, Hongjie Yu, Heather J Zar, Harry Campbell, Harish Nair
BACKGROUND: We have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in 55 000 to 199 000 deaths in children younger than 5 years in 2005. In the past 5 years, major research activity on RSV has yielded substantial new data from developing countries. With a considerably expanded dataset from a large international collaboration, we aimed to estimate the global incidence, hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015...
July 6, 2017: Lancet
https://www.readbyqxmd.com/read/28686692/estimating-influenza-and-respiratory-syncytial-virus-associated-mortality-in-western-kenya-using-health-and-demographic-surveillance-system-data-2007-2013
#4
Gideon O Emukule, Peter Spreeuwenberg, Sandra S Chaves, Joshua A Mott, Stefano Tempia, Godfrey Bigogo, Bryan Nyawanda, Amek Nyaguara, Marc-Alain Widdowson, Koos van der Velden, John W Paget
BACKGROUND: Influenza and respiratory syncytial virus (RSV) associated mortality has not been well-established in tropical Africa. METHODS: We used the negative binomial regression method and the rate-difference method (i.e. deaths during low and high influenza/RSV activity months), to estimate excess mortality attributable to influenza and RSV using verbal autopsy data collected through a health and demographic surveillance system in Western Kenya, 2007-2013. Excess mortality rates were calculated for a) all-cause mortality, b) respiratory deaths (including pneumonia), c) HIV-related deaths, and d) pulmonary tuberculosis (TB) related deaths...
2017: PloS One
https://www.readbyqxmd.com/read/28679495/dose-selection-for-an-adjuvanted-respiratory-syncytial-virus-f-protein-vaccine-for-older-adults-based-on-humoral-and-cellular-immune-responses
#5
Judith Falloon, Keipp Talbot, Craig Curtis, John Ervin, Diane Krieger, Filip Dubovsky, Therese Takas, Jing Yu, Li Yu, Stacie L Lambert, Tonya Villafana, Mark T Esser
This is the second phase 1 study of a respiratory syncytial virus (RSV) vaccine containing RSV fusion protein (sF) adjuvanted with glucopyranosyl lipid A in 2% stable emulsion (GLA-SE). In this randomized, double-blind study (NCT02289820, clinicaltrials.gov), 261 subjects aged ≥60 years received inactivated influenza vaccine (IIV) or a vaccine containing 120 μg sF with escalating doses of GLA (1, 2.5, or 5 μg) in SE or a vaccine containing 80 μg sF with 2.5 μg GLA in SE. Subjects receiving 120 μg sF with 2...
July 5, 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28652534/poly-u-and-cpg-ameliorate-the-unbalanced-t-cell-immunity-and-pneumonia-of-mice-with-rsv-vaccine-enhanced-disease
#6
Ran Jia, Lu Lu, Xiaozhen Liang, Zhiwu Sun, Lingbing Tan, Menghua Xu, Liyun Su, Jin Xu
Respiratory Syncycial Virus (RSV) is the most important pathogen responsible for children's severe lower respiratory tract infection. So far no RSV vaccine has yet been authorized for clinical use. The main impediment that blocked development of RSV vaccine is that inactivated RSV vaccine could cause RSV vaccine-enhanced disease (RVED). The mechanism of RVED remains unclear. Recently some researchers found that insufficient activation of innate immunity, including Toll-like receptors (TLRs), might be associated with the onset of RVED...
June 26, 2017: Bioscience Trends
https://www.readbyqxmd.com/read/28646954/development-of-respiratory-syncytial-virus-rsv-vaccines-for-infants
#7
Hannah E Gerretsen, Charles J Sande
2017 will mark the 60(th) anniversary since the first isolation of RSV in children. In spite of concerted efforts over all these years, the goal of developing an effective vaccine against paediatric RSV disease has remained elusive. One of the main hurdles standing in the way of an effective vaccine is the fact that the age incidence of severe disease peaks within the first 3 months of life, providing limited opportunity for intervention. In addition to this complexity, the spectre of failed historical vaccines, which increased the risk of illness and death upon subsequent natural infection, has substantially increased the safety criteria against which modern vaccines will be assessed...
June 2017: Journal of Infection
https://www.readbyqxmd.com/read/28624306/preclinical-assessment-of-safety-of-maternal-vaccination-against-respiratory-syncytial-virus-rsv-in-cotton-rats
#8
Jorge C G Blanco, Lioubov M Pletneva, Raymonde O Otoa, Mira C Patel, Stefanie N Vogel, Marina S Boukhvalova
Maternal immunization directed to control RSV infection in newborns and infants is an appealing vaccination strategy currently under development. In this work we have modeled maternal vaccination against RSV in cotton rats (CR) to answer two fundamental questions on maternal vaccine safety. We tested (i), whether a known, unsafe RSV vaccine (i.e., FI-RSV Lot 100 vaccine) induces vaccine enhanced disease in the presence of passively transferred, RSV maternal immunity, and (ii) whether the same FI-RSV vaccine could induce vaccine enhanced disease in CR litters when used to immunize their RSV-primed mothers...
July 13, 2017: Vaccine
https://www.readbyqxmd.com/read/28574729/respiratory-syncytial-virus-prospects-for-new-and-emerging-therapeutics
#9
Patricia A Jorquera, Ralph A Tripp
Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infections (LRTI) in infants, the elderly, and the immunocompromised. Although the development of a RSV vaccine has been a priority for >50 years, there is still no vaccine available. Treatment of RSV LRTI has remained mostly supportive, i.e. hydration and oxygenation. Palivizumab and ribavirin are the only options currently available for prevention and treatment of RSV infection, but evidence suggests that they are not fully effective...
August 2017: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/28558308/age-predicts-cytokine-kinetics-and-innate-immune-cell-activation-following-intranasal-delivery-of-ifn%C3%AE-and-gm-csf-in-a-mouse-model-of-rsv-infection
#10
Katherine M Eichinger, Erin Resetar, Jacob Orend, Kacey Anderson, Kerry M Empey
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in young children and is further associated with increased healthcare utilization and cost of care in the first years of life. Severe RSV disease during infancy has also been linked to the later development of allergic asthma, yet there remains no licensed RSV vaccine or effective treatment. Pre-clinical and clinical studies have shown that disease severity and development of allergic asthma are associated with differences in cytokine production...
May 27, 2017: Cytokine
https://www.readbyqxmd.com/read/28539444/improved-prefusion-stability-optimized-codon-usage-and-augmented-virion-packaging-enhance-the-immunogenicity-of-respiratory-syncytial-virus-rsv-fusion-protein-in-a-vectored-vaccine-candidate
#11
Bo Liang, Joan O Ngwuta, Sonja Surman, Barbora Kabatova, Xiang Liu, Matthias Lingemann, Xueqiao Liu, Lijuan Yang, Richard Herbert, Joanna Swerczek, Man Chen, Syed M Moin, Azad Kumar, Jason S McLellan, Peter D Kwong, Barney S Graham, Peter L Collins, Shirin Munir
Respiratory syncytial virus (RSV) is the most important viral agent of severe pediatric respiratory tract disease worldwide, but lacks a licensed vaccine or suitable antiviral drug. A live-attenuated chimeric bovine/human parainfluenza virus type-3 (rB/HPIV3) was developed previously as a vector expressing RSV fusion (F) protein to confer bivalent protection against RSV and HPIV3. In a previous clinical trial in virus-naïve children, rB/HPIV3 was well-tolerated but the immunogenicity of wildtype RSV F was unsatisfactory...
May 24, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28525961/passive-and-active-immunization-against-respiratory-syncytial-virus-for-the-young-and-old
#12
Tonya Villafana, Judith Falloon, M Pamela Griffin, Qing Zhu, Mark T Esser
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants worldwide and also causes significant disease in the elderly. Despite 60 years of RSV research and vaccine development, there is only one approved medicine to prevent RSV infections. Palivizumab, a monoclonal antibody (mAb) against the RSV fusion (F) protein, is indicated for preterm infants and children at high-risk for RSV infections. It is an active time in RSV vaccine and mAb development with 14 vaccines and 2 mAbs currently being tested in clinical trials as of 13 February 2017...
July 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28508217/bac-based-recovery-of-recombinant-respiratory-syncytial-virus-rsv
#13
Christopher C Stobart, Anne L Hotard, Jia Meng, Martin L Moore
Respiratory syncytial virus (RSV) is an enveloped, nonsegmented negative-strand RNA virus, which causes lower respiratory tract infections and is a leading cause of mortality in young infants. There is no available RSV vaccine and currently administered prophylactic antibodies are limited to high-risk populations. Current efforts to develop vaccines include development of live-attenuated RSV candidates. We describe here methods for preparation and recovery of recombinant RSV using an efficient bacterial artificial chromosome (BAC)-based system, expansion and plaque purification of recovered virus, and generation of master and working stocks...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28500974/ongoing-developments-in-rsv-prophylaxis-a-clinician-s-analysis
#14
REVIEW
Fariba Rezaee, Debra T Linfield, Terri J Harford, Giovanni Piedimonte
Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and young children worldwide. Lower respiratory tract infection due to RSV is one of the most common causes of hospitalization for infants, especially those born premature or with chronic lung or heart disease. Furthermore, RSV infection is an important cause of morbidity in adults, particularly in the elderly and immunocompromised individuals. The acute phase of this infection is often followed by episodes of wheezing that recur for months or years and usually lead to a physician diagnosis of asthma...
May 10, 2017: Current Opinion in Virology
https://www.readbyqxmd.com/read/28476625/a-multi-laboratory-study-of-diverse-rsv-neutralization-assays-indicates-feasibility-for-harmonization-with-an-international-standard
#15
Nancy Hosken, Brian Plikaytis, Carrie Trujillo, Kutub Mahmood, Deborah Higgins
A current barrier to the standardized evaluation of respiratory syncytial virus (RSV) vaccine candidates is the wide variety of virus neutralization assay formats currently in use for assessing immunogenicity. Assay formats vary widely in labor intensiveness, duration, and sample throughput. Furthermore, the cell lines and virus strains used are not consistent among formats. The purpose of this multi-laboratory study was to assess the variability across a diverse array of assay formats that quantitate RSV neutralizing antibodies...
May 25, 2017: Vaccine
https://www.readbyqxmd.com/read/28469033/a-highly-potent-extended-half-life-antibody-as-a-potential-rsv-vaccine-surrogate-for-all-infants
#16
Qing Zhu, Jason S McLellan, Nicole L Kallewaard, Nancy D Ulbrandt, Susan Palaszynski, Jing Zhang, Brian Moldt, Anis Khan, Catherine Svabek, Josephine M McAuliffe, Daniel Wrapp, Nita K Patel, Kimberly E Cook, Bettina W M Richter, Patricia C Ryan, Andy Q Yuan, JoAnn A Suzich
Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health priority. However, no vaccine is currently available to protect this vulnerable population. Palivizumab, the only approved agent for RSV prophylaxis, is limited to high-risk infants, and the cost associated with the requirement for dosing throughout the RSV season makes its use impractical for all infants. We describe the development of a monoclonal antibody as potential RSV prophylaxis for all infants with a single intramuscular dose...
May 3, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28413132/development-of-an-intradermal-dna-vaccine-delivery-strategy-to-achieve-single-dose-immunity-against-respiratory-syncytial-virus
#17
Trevor R F Smith, Katherine Schultheis, Matthew P Morrow, Kimberly A Kraynyak, Jay R McCoy, Kevin C Yim, Karuppiah Muthumani, Laurent Humeau, David B Weiner, Niranjan Y Sardesai, Kate E Broderick
Respiratory syncytial virus (RSV) is a massive medical burden in infants, children and the elderly worldwide, and an effective, safe RSV vaccine remains an unmet need. Here we assess a novel vaccination strategy based on the intradermal delivery of a SynCon® DNA-based vaccine encoding engineered RSV-F antigen using a surface electroporation device (SEP) to target epidermal cells, in clinically relevant experimental models. We demonstrate the ability of this strategy to elicit robust immune responses. Importantly we demonstrate complete resistance to pulmonary infection at a single low dose of vaccine in the cotton rat RSV/A challenge model...
April 13, 2017: Vaccine
https://www.readbyqxmd.com/read/28410812/cd4-t-cells-support-establishment-of-rsv-specific-igg-and-iga-antibody-secreting-cells-in-the-upper-and-lower-murine-respiratory-tract-following-rsv-infection
#18
Robert E Sealy, Sherri L Surman, Julia L Hurwitz
The RSV vaccine field suffered a major set-back when children were vaccinated with a formalin-inactivated RSV vaccine (FI-RSV). Unexpectedly, the vaccinated children fared worse than unvaccinated children when they were naturally infected with RSV. Mouse models were then developed that implicated the CD4(+) T helper cell population as a contributor to adverse events. Today, the T cell is viewed with much caution in the RSV field, and its induction by vaccination is sometimes discouraged. Here we re-emphasize the beneficial role of the CD4(+) T cell...
May 9, 2017: Vaccine
https://www.readbyqxmd.com/read/28404847/characterization-of-pre-f-gcn4t-a-modified-human-respiratory-syncytial-virus-fusion-protein-stabilized-in-a-noncleaved-prefusion-conformation
#19
Normand Blais, Martin Gagné, Yoshitomo Hamuro, Patrick Rheault, Martine Boyer, Ann-Muriel Steff, Guy Baudoux, Vincent Dewar, Josée Demers, Jean-Louis Ruelle, Denis Martin
The human respiratory syncytial virus (hRSV) fusion (F) protein is considered a major target of the neutralizing antibody response to hRSV. This glycoprotein undergoes a major structural shift from the prefusion (pre-F) to the postfusion (post-F) state at the time of virus-host cell membrane fusion. Recent evidences suggest that the pre-F state is a superior target for neutralizing antibodies compared to the post-F state. Therefore, for vaccine purposes, we have designed and characterized a recombinant hRSV F protein, called Pre-F-GCN4t, stabilized in a pre-F conformation...
July 1, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28302410/meeting-report-who-consultation-on-respiratory-syncytial-virus-rsv-vaccine-development-geneva-25-26-april-2016
#20
Birgitte K Giersing, Ruth A Karron, Johan Vekemans, David C Kaslow, Vasee S Moorthy
Respiratory syncytial virus (RSV) is a leading viral cause of respiratory morbidity and mortality in infants and young children worldwide. Low and middle income countries (LMICs) account for approximately 99% of the global mortality estimates in this population, with up to 200,000 RSV deaths per year. The vaccine product development pipeline is diverse with the most advanced clinical candidate currently in phase III efficacy testing in pregnant women. In addition, a long-acting RSV-neutralizing monoclonal antibody (mAb) to be administered at birth to prevent serious RSV-related respiratory disease is in late stage clinical development, as are additional conventional mAb for use in high-risk infants...
March 14, 2017: Vaccine
keyword
keyword
66261
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"